Source: Global Legal Chronicle

Ducentis: Arcutis Biotherapeutics' $400 Million Acquisition of Ducentis BioTherapeutics

Goodwin Procter advised Ducentis BioTherapeutics on the deal. Ducentis BioTherapeutics announced its acquisition by Arcutis Biotherapeutics for up to $400 million. Ducentis BioTherapeutics, a portfolio company of [...]

Read full article »

Ducentis's Competitors | Ducentis's News | Ducentis's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Update CEO

CEO Approval Rating

- -/100

Ducentis is an England-based biotechnology company that develops and commercializes novel therapies for the treatment of inflammation and autoimmune diseases.